首頁
Patented Medicine Prices Review Board

4月 2026Patented Medicine Prices...的市場佔有率分析

The Patented Medicine Prices Review Board is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive.

健康 > 藥房

域名pmprb-cepmb.gc.ca

成立年份--

僱員51 - 200

年度營收--

Patented Medicine Prices Review Board

Patented Medicine Prices Review Board（包含公司地區）

pmprb-cepmb.gc.ca

查看更多網站流量與參與度資訊

Patented Medicine Prices Review Board的熱門網域總造訪量

了解Patented Medicine Prices Review Board市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

pmprb-cepmb.gc.ca5.7K

透過銷售情報查看更多內容

Patented Medicine Prices Review Board的熱門網域平均造訪時長

分析Patented Medicine Prices Review Board參與度指標。

過去 3 個月平均造訪時長

子公司細目

pmprb-cepmb.gc.ca00:00:19

透過銷售情報查看更多內容

Patented Medicine Prices Review Board的熱門網域平均頁面瀏覽量

了解Patented Medicine Prices Review Board如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

pmprb-cepmb.gc.ca1.53

透過銷售情報查看更多內容

Patented Medicine Prices Review Board按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Patented Medicine Prices Review Board

这些是Patented Medicine Prices Review Board顶级域名使用的行业网站技术

行動裝置 (2)

Meta Viewport

付款與貨幣 (2)

Visa

音訊視訊媒體 (1)

YouTube

轉換與分析 (1)

Google Analytics

更多技術

3

檢視所有

新聞與訊號來自Patented Medicine Prices Review Board

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Patented Medicine Prices Review Board launched Discussion Guide on Apr 15th '24.The next phase of the PMPRB's consultation will begin in summer 2024 with the release of a Discussion Guide.

新聞Patented Medicine Prices Review Board launched Scoping Paper for the Consultations on the Board's Guidelines on Nov 10th '23.On November 10, 2023, the PMPRB published its Scoping Paper for the Consultations on the Board's Guidelines.

新聞Patented Medicine Prices Review Board launches Meds Pipeline Monitor 2022 report.The Patented Medicine Prices Review Board (PMPRB) recently published its Meds Pipeline Monitor 2022 report, which highlights medicines in the pipeline that may impact future clinical practice and drug spending in Canada if approved for sale.